Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis

SIMPLE SUMMARY: The treatment of anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) advanced non-small cell lung cancer (NSCLC) remains a challenge. We compared the safety and efficacy of lorlatinib and alectinib in patients with ALK-p ALK-inhibitor‒naïve advanced NSCLC (in overall part...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Manabe, Ryo, Kishino, Yasunari, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345181/
https://www.ncbi.nlm.nih.gov/pubmed/34359604
http://dx.doi.org/10.3390/cancers13153704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345181/
https://www.ncbi.nlm.nih.gov/pubmed/34359604
http://dx.doi.org/10.3390/cancers13153704

Ejemplares similares